Pain and Pain Management

  • Abigail E. FranklinEmail author
  • Melanie R. Lovell
Reference work entry


Pain is one of the most common symptoms encountered in palliative medicine. Good pain management involves ensuring pain is screened for, adequately assessed if present and appropriately managed. This includes targeted and systemic, nonpharmacological, and pharmacological approaches. This chapter seeks to give an evidence-based overview of approaches to screening for assessing and managing a patient’s pain.


  1. Abbey J, Piller N, De Bellis A, Esterman A, Parker D, Giles L, Lowcay B. The Abbey pain scale: a 1-minute numerical indicator for people with end-stage dementia. Int J Palliat Nurs. 2004;10(1):6–13.PubMedCrossRefPubMedCentralGoogle Scholar
  2. Actavis. Product information fentanyl TD. 2012.Google Scholar
  3. Ale I, Lachapelle JM, Maibach HI. Skin tolerability associated with transdermal drug delivery systems: an overview. Adv Ther. 2009;26(10):920–35.PubMedCrossRefPubMedCentralGoogle Scholar
  4. ANZCA, FPM. Opioid calculator app. 2017. Retrieved 22nd January, 2017.Google Scholar
  5. Archie P, Bruera E, Cohen L. Music-based interventions in palliative cancer care: a review of quantitative studies and neurobiological literature. Support Care Cancer. 2013;21(9):2609–24.PubMedCrossRefPubMedCentralGoogle Scholar
  6. Arcidiacono PG, Calori G, Carrara S, McNicol ED, Testoni PA. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011;3Google Scholar
  7. Australian Adult Cancer Pain Management Guideline Working Party. Cancer pain management in adults. Cancer guidelines wiki. Sydney, Cancer Council Australia; 2016.Google Scholar
  8. Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust. 2000;173:536–40.PubMedPubMedCentralGoogle Scholar
  9. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol. 2015; 34(5):436–442.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Bao Y, Kong X, Yang L, Liu R, Shi Z, Li W, Hua B, Hou W. Complementary and alternative medicine for cancer pain: an overview of systematic reviews. Evid Based Complement Alternat Med. 2014;2014(9):170396.PubMedPubMedCentralGoogle Scholar
  11. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev. 2017;6:CD003351.PubMedPubMedCentralGoogle Scholar
  12. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The faces pain scale for the self-assessment of the severity of pain experienced by children: development, initial validation, and preliminary investigation for ratio scale properties. Pain. 1990;41(2):139–50.PubMedCrossRefPubMedCentralGoogle Scholar
  13. BioCSL. Versartis product information. 2015.Google Scholar
  14. Boyd C, Crawford C, Paat CF, Price A, Xenakis L, Zhang W. The impact of massage therapy on function in pain populations – a systematic review and meta-analysis of randomized controlled trials: part II, cancer pain populations. Pain Med. 2016;17(8):1553–68. pnw100PubMedCrossRefPubMedCentralGoogle Scholar
  15. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835–42.PubMedCrossRefPubMedCentralGoogle Scholar
  16. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain. 1999;82(3):263–74.PubMedCrossRefPubMedCentralGoogle Scholar
  17. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European palliative care research collaborative guidelines project. Palliat Med. 2011;25(5):402–9.PubMedCrossRefPubMedCentralGoogle Scholar
  18. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, Dale O, De Conno F, Fallon M, Hanna M, Haugen DF, Juhl G, King S, Klepstad P, Laugsand EA, Maltoni M, Mercadante S, Nabal M, Pigni A, Radbruch L, Reid C, Sjogren P, Stone PC, Tassinari D, Zeppetella G. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13(2):e58–68.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev. 2005;4:CD003345.Google Scholar
  20. Chambers WA. Nerve blocks in palliative care. Br J Anaesth. 2008;101(1):95–100.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, Brundage M, DeAngelis C, Wong RKS. Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: a double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(15):1463–72.PubMedCrossRefPubMedCentralGoogle Scholar
  22. Cleeland CS. The brief pain inventory user guide. M D Anderson Cancer Centre; 2009.Google Scholar
  23. Corrigan R, Derry S, Wiffen PJ, Moore RA. Clonazepam for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;(5).Google Scholar
  24. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95(4):376–82.PubMedCrossRefPubMedCentralGoogle Scholar
  25. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387(10033):2093–105.PubMedCrossRefPubMedCentralGoogle Scholar
  26. Dale O, Moksnes K, Kaasa S. European palliative care research collaborative pain guidelines: opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med. 2011;25(5):494–503.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Davis MP, Temel JS, Balboni T, Glare P. A review of the trials which examine early integration of outpatient and home palliative care for patients with serious illnesses. Ann Palliat Med. 2015;4(3):99–121.PubMedPubMedCentralGoogle Scholar
  28. de Courcy JG. Interventional techniques for cancer pain management. Clin Oncol (R Coll Radiol). 2011;23(6):407–17.CrossRefGoogle Scholar
  29. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19(12):1985–91.PubMedCrossRefPubMedCentralGoogle Scholar
  30. Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for neuropathic pain in adults. Cochrane Database Syst Rev. 2015a;(7).Google Scholar
  31. Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015b;(1).Google Scholar
  32. Derry S, Wiffen PJ, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017;7:CD012638.PubMedPubMedCentralGoogle Scholar
  33. Dong ST, Butow PN, Costa DSJ, Lovell MR, Agar M. Symptom clusters in patients with advanced cancer: a systematic review of observational studies. J Pain Symptom Manag. 2014;48(3):411–50.CrossRefGoogle Scholar
  34. Duehmke RM, Derry S, Wiffen PJ, Bell RF, Aldington D, Moore RA. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD003726.PubMedPubMedCentralGoogle Scholar
  35. Eccleston C, Hearn L, Williams AC. Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2015;10:CD011259.Google Scholar
  36. European Federation of Neurological Societies Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, Hardiman O, Kollewe K, Morrison KE, Petri S, Pradat P-F, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–75.Google Scholar
  37. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105–11.PubMedCrossRefPubMedCentralGoogle Scholar
  38. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice ASC, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73.PubMedCrossRefPubMedCentralGoogle Scholar
  39. Fleming JAOC, B.D. Use of lidocaine patches for neuropathic pain in a comprehensive cancer Centre. Pain Res Manag. 2009;14(5):381–8.PubMedCrossRefPubMedCentralGoogle Scholar
  40. France BD, Lewis RA, Sharma ML, Poolman M. Cordotomy in mesothelioma-related pain: a systematic review. BMJ Support Palliat Care. 2014;4(1):19–29.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(8).Google Scholar
  42. Garzon-Rodriguez C, Casals Merchan M, Calsina-Berna A, Lopez-Romboli E, Porta-Sales J. Lidocaine 5% patches as an effective short-term co-analgesic in cancer pain. Preliminary results. Support Care Cancer. 2013;21(11):3153–8.PubMedCrossRefPubMedCentralGoogle Scholar
  43. Gill D, Derry S, Wiffen PJ, Moore RA. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(10).Google Scholar
  44. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879–923.PubMedCrossRefPubMedCentralGoogle Scholar
  45. Hardy JR, Rees EAJ, Gwilliam B, Ling J, Broadley K, A’Hern R. A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manag. 2001;21(3):204–9.CrossRefGoogle Scholar
  46. Hadley G, Derry S, Moore RA, Wiffen PJ. Transdermal fentanyl for cancer pain. Cochrane Database Syst Rev. 2013;10:CD010270.Google Scholar
  47. Hans G, Robert D. Transdermal buprenorphine – a critical appraisal of its role in pain management. J Pain Res. 2009;2:117–34.PubMedCrossRefPubMedCentralGoogle Scholar
  48. Haywood A, Good P, Khan S, Leupp A, Jenkins-Marsh S, Rickett K, Hardy JR. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst Rev. 2015;4:CD010756.Google Scholar
  49. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;(2).Google Scholar
  50. Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014a;(5).Google Scholar
  51. Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014b;(9).Google Scholar
  52. Hebert D, Lindsay MP, McIntyre A, Kirton A, Rumney PG, Bagg S, Bayley M, Dowlatshahi D, Dukelow S, Garnhum M, Glasser E, Halabi M-L, Kang E, MacKay-Lyons M, Martino R, Rochette A, Rowe S, Salbach N, Semenko B, Stack B, Swinton L, Weber V, Mayer M, Verrilli S, DeVeber G, Andersen J, Barlow K, Cassidy C, Dilenge M-E, Fehlings D, Hung R, Iruthayarajah J, Lenz L, Majnemer A, Purtzki J, Rafay M, Sonnenberg LK, Townley A, Janzen S, Foley N, Teasell R. Canadian stroke best practice recommendations: stroke rehabilitation practice guidelines, update 2015. Int J Stroke. 2016;11(4):459–84.PubMedCrossRefPubMedCentralGoogle Scholar
  53. Heiskanen T, Matzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1–2):218–22.PubMedCrossRefPubMedCentralGoogle Scholar
  54. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and Metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.PubMedCrossRefPubMedCentralGoogle Scholar
  55. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Rev Neurosci. 2001;2:83.PubMedCrossRefPubMedCentralGoogle Scholar
  56. Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. Cochrane Database Syst Rev. 2012;3:CD006276.Google Scholar
  57. International Association for the Study of Pain. Total cancer pain. 2009.Google Scholar
  58. International Association for the Study of Pain. IASP taxonomy.2017. Retrieved 19 Nov 2017, from
  59. Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013;48(7):830–8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. Johnson MI, Mulvey MR, Bagnall A-M. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. Cochrane Database Syst Rev. 2015a;8:CD007264.PubMedPubMedCentralGoogle Scholar
  61. Johnson MI, Paley CA, Howe TE, Sluka KA. Transcutaneous electrical nerve stimulation for acute pain. Cochrane Database Syst Rev. 2015b;6:CD006142.Google Scholar
  62. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018;12(2):108–17.PubMedPubMedCentralGoogle Scholar
  63. King S, Forbes K, Hanks G, Ferro C, Chambers E. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European palliative care research collaborative opioid guidelines project. Palliat Med. 2011;25(5):525–52.PubMedCrossRefPubMedCentralGoogle Scholar
  64. Kjellberg F, Tramèr MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol. 2001;18:346–57.PubMedCrossRefPubMedCentralGoogle Scholar
  65. Klepstad P, Kaasa S, Borchgrevink PC. Starting step III opioids for moderate to severe pain in cancer patients: dose titration: a systematic review. Palliat Med. 2011;25(5):424–30.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Kane CM, Mulvey MR, Wright S, Craigs C, Wright JM, Bennett MI. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: systematic review and meta-analysis. Palliat Med. 2017;32(1):276–86.PubMedCrossRefPubMedCentralGoogle Scholar
  67. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13(3):219–30.PubMedCrossRefPubMedCentralGoogle Scholar
  68. Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25(5):442–53.PubMedCrossRefPubMedCentralGoogle Scholar
  69. Leppert W. The role of methadone in cancer pain treatment – a review. Int J Clin Pract. 2009;63(7):1095–109.PubMedCrossRefPubMedCentralGoogle Scholar
  70. Lickiss JN. Approaching cancer pain relief. Eur J Pain. 2001;5(Suppl A):5–14.PubMedCrossRefPubMedCentralGoogle Scholar
  71. Løhre ET, Klepstad P, Bennett MI, Brunelli C, Caraceni A, Fainsinger RL, Knudsen AK, Mercadante S, Sjøgren P, Kaasa S. From “breakthrough” to “episodic” cancer pain? A European Association for palliative care research network expert Delphi survey toward a common terminology and classification of transient cancer pain exacerbations. J Pain Symptom Manag. 2016;51(6):1013–9.CrossRefGoogle Scholar
  72. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;(1).Google Scholar
  73. Lynn TRD, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, Staats PS, Wallace M. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14:E283–312.Google Scholar
  74. Marie N, Luckett T, Davidson PM, Lovell M, Lal S. Optimal patient education for cancer pain: a systematic review and theory-based meta-analysis. Support Care Cancer. 2013;21(12):3529–37.PubMedCrossRefPubMedCentralGoogle Scholar
  75. McConnell T, Scott D, Porter S. Music therapy for end-of-life care: an updated systematic review. Palliat Med. 2016;30:877–83.PubMedCrossRefPubMedCentralGoogle Scholar
  76. McLean S, Twomey F. Methods of rotation from another strong opioid to methadone for the management of cancer pain: a systematic review of the available evidence. J Pain Symptom Manag. 2015;50(2):248–59. e241CrossRefGoogle Scholar
  77. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;(8).Google Scholar
  78. McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013;8:CD008025.Google Scholar
  79. McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;5:CD012499.PubMedPubMedCentralGoogle Scholar
  80. Meier T, Wasner G, Faust M, Kuntzer T, Ochsner F, Hueppe M, Bogousslavsky J, Baron R. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106(1):151–8.PubMedCrossRefPubMedCentralGoogle Scholar
  81. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971–9.PubMedCrossRefPubMedCentralGoogle Scholar
  82. Mercadante S, Caraceni A. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med. 2011;25(5):504–15.PubMedCrossRefPubMedCentralGoogle Scholar
  83. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manag. 2000;20(4):246–52.CrossRefGoogle Scholar
  84. Mercadante S, Porzio G, Aielli F, Adile C, Verna L, Ficorella C, Giarratano A, Casuccio A. Opioid switching from and to tapentadol extended release in cancer patients: conversion ratio with other opioids. Curr Med Res Opin. 2013;29(6):661–6.PubMedCrossRefPubMedCentralGoogle Scholar
  85. Mercadante S, Klepstad P, Kurita GP, Sjogren P, Giarratano A, European Palliative Care Research Centre. Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations. Crit Rev Oncol Hematol. 2015;96(3):577–83.PubMedCrossRefPubMedCentralGoogle Scholar
  86. Mhaskar R, Redzepovic J, Wheatley K, Clark OAC, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;5:CD003188.Google Scholar
  87. Miller JL, Hagemann TM. Use of pure opioid antagonists for management of opioid-induced pruritus. Am J Health Syst Pharm. 2011;68(15):1419–25.PubMedCrossRefPubMedCentralGoogle Scholar
  88. Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer. 2008;98(12):1934–43.PubMedCrossRefPubMedCentralGoogle Scholar
  89. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009;(3).Google Scholar
  90. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015a;(7).Google Scholar
  91. Moore RA, Wiffen PJ, Derry S, Lunn MPT. Zonisamide for neuropathic pain in adults. Cochrane Database Syst Rev. 2015b;(1).Google Scholar
  92. National Clinical Effectiveness Committee. Pharmacological management of cancer pain in adults. 2016.Google Scholar
  93. National Comprehensive Cancer Network. Adult cancer pain. 2016.Google Scholar
  94. NICE. Neuropathic pain in adults: pharmacological management in non-specialist settings. 2013.Google Scholar
  95. Nicholson AB, Watson GR, Derry S, Wiffen PJ. Methadone for cancer pain. Cochrane Database Syst Rev. 2017;2:CD003971.PubMedPubMedCentralGoogle Scholar
  96. O’Carrigan B, Wong MHF, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.PubMedPubMedCentralGoogle Scholar
  97. Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC. A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain. 2015;16(10):935–46.PubMedCrossRefPubMedCentralGoogle Scholar
  98. Paley CA, Johnson MI, Tashani OA, Bagnall A-M. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2015;10:CD007753.Google Scholar
  99. Pasternak GW. Opioids and their receptors: are we there yet? Neuropharmacology. 2014;76, Part B:198–203.CrossRefGoogle Scholar
  100. Paulsen O, Aass N, Kaasa S, Dale O. Do corticosteroids provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manag. 2013;46(1):96–105.CrossRefGoogle Scholar
  101. Paulsen O, Klepstad P, Rosland JH, Aass N, Albert E, Fayers P, Kaasa S. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 2014;32(29):3221–8.PubMedCrossRefPubMedCentralGoogle Scholar
  102. Peixoto RDA, Hawley P. Intravenous lidocaine for cancer pain without electrocardiographic monitoring: a retrospective review. J Palliat Med. 2014;18(4):373–7.PubMedCrossRefPubMedCentralGoogle Scholar
  103. Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015;6:CD009389.Google Scholar
  104. Porta-Sales J, Garzon-Rodriguez C, Llorens-Torrome S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for palliative care guidelines project. Palliat Med. 2017;31(1):5–25.PubMedCrossRefPubMedCentralGoogle Scholar
  105. Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. J Clin Oncol. 2014;32(16):1662–70.PubMedCrossRefPubMedCentralGoogle Scholar
  106. Prommer EE. Ketamine for pain: an update of uses in palliative care. J Palliat Med. 2012;15(4):474–83.PubMedCrossRefPubMedCentralGoogle Scholar
  107. Pruskowski J, Arnold RM. A comparison of pregabalin and gabapentin in palliative care #289. J Palliat Med. 2015;18(4):386–7.PubMedCrossRefPubMedCentralGoogle Scholar
  108. Puchalski C, Ferrell B, Virani R, Otis-Green S, Baird P, Bull J, Chochinov H, Handzo G, Nelson-Becker H, Prince-Paul M, Pugliese K, Sulmasy D. Improving the quality of spiritual care as a dimension of palliative care: the report of the consensus conference. J Palliat Med. 2009;12(10):885–904.PubMedCrossRefPubMedCentralGoogle Scholar
  109. Rayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, Heitzer E, Fainsinger R, Bennett MI, Collaborative O b o t EPCR. Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative–Computerised Symptom Assessment study. Palliat Med. 2013;27(8):714–21.PubMedCrossRefPubMedCentralGoogle Scholar
  110. Reich A, Szepietowski JC. Opioid-induced pruritus: an update. Clin Exp Dermatol. 2010;35(1):2–6.PubMedCrossRefPubMedCentralGoogle Scholar
  111. Royal Australian College of General Practitioners. Pharmaceutical Society of Australia. Australian Medicines Handbook. 2016.Google Scholar
  112. Rueda J-R, Solà I, Pascual A, Subirana Casacuberta M. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database Syst Rev. 2011;9:CD004282.Google Scholar
  113. Salas S, Frasca M, Planchet-Barraud B, Burucoa B, Pascal M, Lapiana JM, Hermet R, Castany C, Ravallec F, Loundou A, Auquier P, Duffaud F, Baumstarck K. Ketamine analgesic effect by continuous intravenous infusion in refractory cancer pain: considerations about the clinical research in palliative care. J Palliat Med. 2012;15(3):287–93.PubMedCrossRefPubMedCentralGoogle Scholar
  114. Sande TA, Laird BJ, Fallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer. 2017;25(2):661–75.PubMedCrossRefPubMedCentralGoogle Scholar
  115. Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS. Buprenorphine for treating cancer pain. Cochrane Database Syst Rev. 2015;3:CD009596.Google Scholar
  116. Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS. Oxycodone for cancer-related pain. Cochrane Database Syst Rev. 2017;8:CD003870.PubMedPubMedCentralGoogle Scholar
  117. Schug SA, Palmer G, Sco DA, Halliwell R, Trinca J. APM:SE working group of the Australian and New Zealand college of Anaesthetists and Faculty of Pain Medicine. Melbourne: ANZCA and FPM; 2015.Google Scholar
  118. Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer. Scottish Intercollegiate Guidelines Network: Edinburgh; 2008.Google Scholar
  119. Scottish Partnership for Palliative Care. Scottish palliative care guidelines. 2013, 2016. Retrieved 22 Jan 2017, from
  120. Seah DS, Herschtal A, Tran H, Thakerar A, Fullerton S. Subcutaneous lidocaine infusion for pain in patients with cancer. J Palliat Med. 2016; 20(6):667–71.PubMedCrossRefPubMedCentralGoogle Scholar
  121. Shaiova L, Berger A, Blinderman CD, Bruera E, Davis MP, Derby S, Inturrisi C, Kalman J, Mehta D, Pappagallo M, Perlov E. Consensus guideline on parenteral methadone use in pain and palliative care. Palliat Support Care. 2008;6(2):165–76.PubMedCrossRefPubMedCentralGoogle Scholar
  122. Sharma S, Rajagopal MR, Palat G, Singh C, Haji AG, Jain D. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manag. 2009;37(1):85–93.CrossRefGoogle Scholar
  123. Sheinfeld Gorin S, Krebs P, Badr H, Janke EA, Jim HSL, Spring B, Mohr DC, Berendsen MA, Jacobsen PB. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol. 2012;30(5):539–47.PubMedCrossRefPubMedCentralGoogle Scholar
  124. Shepherd TM, Hoch MJ, Cohen BA, Bruno MT, Fieremans E, Rosen G, Pacione D, Mogilner AY. Palliative CT-guided Cordotomy for medically intractable pain in patients with cancer. AJNR Am J Neuroradiol. 2017;38(2):387–90.PubMedCrossRefPubMedCentralGoogle Scholar
  125. Shin E-S, Seo K-H, Lee S-H, Jang J-E, Jung Y-M, Kim M-J, Yeon J-Y. Massage with or without aromatherapy for symptom relief in people with cancer. Cochrane Database Syst Rev. 2016;6:CD009873.Google Scholar
  126. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manag. 2006;31(1):58–69.CrossRefGoogle Scholar
  127. Sperlinga R, Campagna S, Berruti A, Laciura P, Ginosa I, Paoletti S, Giuliano PL, Tucci M, Rosato R, Scagliotti GV, Saini A. Alberta breakthrough pain assessment tool: a validation multicentre study in cancer patients with breakthrough pain. Eur J Pain. 2015;19(7):881–8.PubMedCrossRefPubMedCentralGoogle Scholar
  128. Stannard C, Gaskell H, Derry S, Aldington D, Cole P, Cooper TE, Knaggs R, Wiffen PJ, Moore RA. Hydromorphone for neuropathic pain in adults. Cochrane Database Syst Rev. 2016;5:CD011604.Google Scholar
  129. Straube C, Derry S, Jackson KC, Wiffen PJ, Bell RF, Strassels S, Straube S. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database Syst Rev. 2014;9:CD006601.Google Scholar
  130. Syrmis W, Good P, Wootton J, Spurling G. Opioid conversion ratios used in palliative care: is there an Australian consensus? Intern Med J. 2014;44(5):483–9.PubMedCrossRefPubMedCentralGoogle Scholar
  131. Tassinari D, Drudi F, Rosati M, Tombesi P, Sartori S, Maltoni M. The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med. 2011;25(5):410–23.PubMedCrossRefPubMedCentralGoogle Scholar
  132. Tatrow K, Montgomery GH. Cognitive behavioral therapy techniques for distress and pain in breast cancer patients: a meta-analysis. J Behav Med. 2006;29(1):17–27.PubMedCrossRefPubMedCentralGoogle Scholar
  133. Thomas J, Kronenberg R, Cox MC, Naco GC, Wallace M, Gunten CF v. Intravenous lidocaine relieves severe pain: results of an inpatient hospice chart review. J Palliat Med. 2004;7(5):660–7.PubMedCrossRefPubMedCentralGoogle Scholar
  134. Twycross R; Wilcock A; Howard P; Palliative care formulary 5th Edition. 2016.Google Scholar
  135. Tyson SF, Kent RM. The effect of upper limb orthotics after stroke: a systematic review. NeuroRehabilitation. 2011;28(1):29–36.PubMedPubMedCentralGoogle Scholar
  136. Upadhyay SP, Mallick PN. Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates. Am J Hosp Palliat Care. 2012;29(5):388–98.PubMedCrossRefPubMedCentralGoogle Scholar
  137. van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag. 2016;51(6):1070–90. e1079CrossRefGoogle Scholar
  138. Vellucci R, Fanelli G, Pannuti R, Peruselli C, Adamo S, Alongi G, Amato F, Consoletti L, Lamarca L, Liguori S, Lo Presti C, Maione A, Mameli S, Marinangeli F, Marulli S, Minotti V, Miotti D, Montanari L, Moruzzi G, Palermo S, Parolini M, Poli P, Tirelli W, Valle A, Romualdi P. What to do, and what not to do, when diagnosing and treating breakthrough cancer pain (BTcP): expert opinion. Drugs. 2016;76(3):315–30.PubMedCrossRefPubMedCentralGoogle Scholar
  139. Ventafridda V, Caraceni A, Gamba A. Field-testing of the WHO guidelines for cancer pain relief-summary report of demonstration projects. Adv Pain Res Ther. 1990;16:451–64.Google Scholar
  140. Webber K, Davies AN, Zeppetella G, Cowie MR. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manag. 2014;48(4):619–31.CrossRefGoogle Scholar
  141. Wen W, Lynch SY, Munera C, Swanton R, Ripa SR, Maibach H. Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. Expert Opin Drug Saf. 2013;12(3):309–19.PubMedCrossRefPubMedCentralGoogle Scholar
  142. Wiffen PJ, Derry S, Lunn MPT, Moore RA. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013a;(8).Google Scholar
  143. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, Lunn MPT, Hamunen K, Haanpaa M, Kalso EA. Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013b;(11).Google Scholar
  144. Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2014a;(4).Google Scholar
  145. Wiffen PJ, Derry S, Moore RA, Lunn MPT. Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev. 2014b;(7).Google Scholar
  146. Wiffen PJ, Derry S, Moore RA, Stannard C, Aldington D, Cole P, Knaggs R. Buprenorphine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015a;9:CD011603.Google Scholar
  147. Wiffen PJ, Derry S, Naessens K, Bell RF. Oral tapentadol for cancer pain. Cochrane Database Syst Rev. 2015b;9:CD011460.Google Scholar
  148. Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA. Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database Syst Rev. 2016a;12:CD012227.PubMedPubMedCentralGoogle Scholar
  149. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2016b;4:CD003868.PubMedPubMedCentralGoogle Scholar
  150. Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017a;5:CD012508.PubMedPubMedCentralGoogle Scholar
  151. Wiffen PJ, Derry S, Moore RA, McNicol ED, Bell RF, Carr DB, McIntyre M, Wee B. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017b;7:CD012637.PubMedPubMedCentralGoogle Scholar
  152. Wong RKS, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;2:CD002068.Google Scholar
  153. Wong MHF, Stockler MR, Pavlakis N. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2012;2:CD003474.Google Scholar
  154. World Health Organisation. Traitement de la doleur cancereuse. Geneva: World Health Organisation; 1987.Google Scholar
  155. World Health Organisation. Cancer pain relief. Geneva: World Health Organisation; 1996.Google Scholar
  156. World Health Organisation. Definition of palliative care. 2016.
  157. Zeppetella G. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project. Palliat Med. 2011;25(5):516–24.PubMedCrossRefPubMedCentralGoogle Scholar
  158. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev. 2015;8:CD004311.Google Scholar
  159. Zhou M, Chen N, He L, Yang M, Zhu C, Wu F. Oxcarbazepine for neuropathic pain. Cochrane Database Syst Rev. 2013;(3).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.HammondCare Palliative and Supportive Care ServiceGreenwich HospitalSydneyAustralia
  2. 2.Northern Clinical School and Kolling InstituteThe University of SydneySydneyAustralia

Personalised recommendations